Skip to main content

Authored Items
First-Line Enasidenib Achieves Complete Remission in Older Patients with Acute Myeloid Leukemia and IDH2 Mutation
Charles Bankhead
January/February 2019, Vol 12, Special Issue: Payers’ Perspectives in Oncology: ASH 2018 Highlights in Leukemia
Checkpoint Inhibition Consolidation Therapy Promising in High-Risk Hematologic Malignancies
Charles Bankhead
January/February 2019, Vol 12, Special Issue: Payers’ Perspectives in Oncology: ASH 2018 Highlights in Lymphoma
Can Technologic Innovations and Formulary Considerations Improve Healthcare Outcomes?
Charles Bankhead
June 2018 Vol 11, No 4 in Conference Highlights AMCP
Ponatinib, a Tyrosine Kinase Inhibitor, Active in Patients with Relapsed or Refractory Chronic Myeloid Leukemia and BCR-ABL T315I Mutation
Charles Bankhead
February 2017 Vol 10, Special Issue: Payers’ Perspectives In Oncology: ASH 2016 Highlights in Leukemia
HIV Drug Shows Promise in Refractory Multiple Myeloma
Charles Bankhead
February 2017 Vol 10, Special Issue: Payers’ Perspectives In Oncology: ASH 2016 Highlights in Multiple Myeloma
Chemotherapy-Free Induction with Ibrutinib plus Rituximab Shows Unprecedented Efficacy in MCL
Charles Bankhead
February 2017 Vol 10, Special Issue: Payers’ Perspectives In Oncology: ASH 2016 Highlights in Leukemia
Novel Hypomethylating Agent Active in Patients with High-Risk Myelodysplastic Syndromes or Chronic Myelomonocytic Leukemia
Charles Bankhead
February 2017 Vol 10, Special Issue: Payers’ Perspectives In Oncology: ASH 2016 Highlights in Emerging Therapies
CAR T-Cell Therapy Highly Active in Various Lymphomas
Charles Bankhead
February 2016 Vol 9, Special Issue: Payers' Perspectives in Oncology
Pharmacoeconomics and Health Insurance Coverage
Charles Bankhead
May/June 2013 Vol 6, No 4 in Conference Highlights AMCP
“Dramatic” Responses with Targeted Agent for Patients with CLL
Charles Bankhead
February 2013 Vol 6, No 1, Special Issue in Leukemia
Last modified: April 11, 2019